What are the triggers and/or ATS/IDSA guidelines that would prompt you use amikacin for MAC lung disease, in either an IV or liposome aerosol suspension formulation? What is the role, based on the CONVERT trial, for the inhalation suspension?

What are the triggers and/or ATS/IDSA guidelines that would prompt you use amikacin for MAC lung disease, in either an IV or liposome aerosol suspension formulation? What is the role, based on the CONVERT trial, for the inhalation suspension?

CLICK HERE FOR CME CREDIT

What are the triggers and/or ATS/IDSA guidelines that would prompt you use amikacin for MAC lung disease, in either an IV or liposome aerosol suspension formulation? What is the role, based on the CONVERT trial, for the inhalation suspension?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Julie Philley, MD

Julie Philley, MD

Chair of the Department of Medicine
Chief of Pulmonary and Critical Care
UT Health North Campus Tyler
The University of Texas Health Sciences Center
Houston, Texas